Limb Girdle Muscular Dystrophy (LGMD)-Market Insights, Epidemiology and Market Forecast-2027

Pages: 100
Geography: Global
Delivery Timeline: 24 hours
Publication: Feb, 2019

SKU: DIMI0482

Single User License
$6250
Buy
Site License
$12500
Buy
Global License
40% Off
$11250
Buy

Request Sample

Name*
Email ID*
Mobile*
Company*
Country*
Zip Code*
Address*
Message*

Request Sample Pages

Request Before Buy

Inquire Before Buy

Send Friend

Send to Friend

DelveInsight’s Limb Girdle Muscular Dystrophy (LGMD)-Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Limb Girdle Muscular Dystrophy (LGMD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Limb Girdle Muscular Dystrophy (LGMD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered

The United States
EU5 (Germany, France, Italy, Spain and the United Kingdom)
Japan

Study Period: 2016-2027
Limb Girdle Muscular Dystrophy (LGMD) - Disease Understanding and Treatment Algorithm
Limb-Girdle Muscular Dystrophy (LGMD) encompasses heterogeneous group of rare, genetic, degenerative muscle disorders; with both childhood and adult-onset dystrophy. It is a genetically inherited condition that primarily affects skeletal muscle leading to progressive, predominantly proximal muscle weakness at presentation caused by a loss of muscle fibers. It is generally characterized by weakness of the shoulder and the pelvic girdle muscles. The mutations in genes leads to the loss of various proteins that are involved in muscle maintenance and repair. There are more than 30 subtypes; within each Limb Girdle Muscular Dystrophy (LGMD) subtype, the severity, age of onset, and features demonstrate a high degree of consistency.
An ENMC Consensus in 2017, classified Limb Girdle Muscular Dystrophy (LGMD) based on its inheritance pattern and clinical characteristics into two types: autosomal dominant (LGMD type 1), autosomal recessive (LGMD type 2). Dominant forms of LGMD have usually a slow course, while recessive form can have an early onset and fast progression, but a number of LGMD2 patients with adult-onset remain ambulant until late in life. The dominant forms are mostly associated with cardiac complications and breathing problems along with muscle wasting.
The DelveInsight Limb Girdle Muscular Dystrophy (LGMD) market report gives the thorough understanding of the LGMD by including details such as disease definition, symptoms, classification, causes, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Limb Girdle Muscular Dystrophy (LGMD) in the US, Europe, and Japan.
Limb Girdle Muscular Dystrophy (LGMD) Epidemiology
The Limb Girdle Muscular Dystrophy (LGMD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalence of Limb-Girdle Muscular Dystrophy, Type specific cases, Severity specific cases, Diagnosed population of Limb-Girdle Muscular Dystrophy] scenario of LGMD in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
As per Corrado Angelini et. Al. the prevalence of all Limb-Girdle Muscular Dystrophy (LGMDs) types ranges from 4-7 per 100,000, depending on the geographical and ethnic origin. Large studies have found that in the specific areas i.e. south Europe, calpainopathy is the most prevalent form, while in Northern Europe calpainopathy can be unfrequent; but LGMD 2I is common. A large proportion of recessive LGMD cases is due to dysferlinopathy, sarcoglycanopathies.
According to National Organization for Rare Disorders, LGMD affects males and females in equal numbers. The prevalence of LGMD is unknown, but estimates range from one in 14,500 to one in 123,000. The age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from population to population.
Limb Girdle Muscular Dystrophy (LGMD) Drug Chapters
This segment of the Limb Girdle Muscular Dystrophy (LGMD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, there is no cure and no FDA approved therapies for the treatment of Limb-Girdle Muscular Dystrophy (LGMD), current research is mostly focused on the use of novel gene therapies in order to treat the underlying genetic changes.
Major pharmaceutical companies, such as Myonexus Therapeutics (MYO-101, MYO-102) and aTyr Pharma (ATYR1940), etc. are involved in the development of novel therapies for the treatment of Limb Girdle Muscular Dystrophy (LGMD).
Limb Girdle Muscular Dystrophy (LGMD) Market Outlook
The Limb Girdle Muscular Dystrophy (LGMD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Limb Girdle Muscular Dystrophy (LGMD) in 7MM is expected to change from the study period 2016-2027.
Limb Girdle Muscular Dystrophy (LGMD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Limb Girdle Muscular Dystrophy (LGMD) Report Insights

Patient Population
Therapeutic Approaches
Pipeline Analysis
Market Size and Trends
Market Opportunities
Impact of upcoming Therapies

Limb Girdle Muscular Dystrophy (LGMD) Report Key Strengths

10 Years Forecast
7MM Coverage
Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Drugs Uptake

Limb Girdle Muscular Dystrophy (LGMD) Report Assessment

Current Treatment Practices
Unmet Needs
Pipeline Product Profiles
Market Attractiveness
Market Drivers and Barriers

Key Benefits

This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Limb Girdle Muscular Dystrophy (LGMD) market
Organize sales and marketing efforts by identifying the best opportunities for Limb Girdle Muscular Dystrophy (LGMD) market
To understand the future market competition in the Limb Girdle Muscular Dystrophy (LGMD) market.

1. Report Introduction
2. Limb-Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance
2.1. Global Market Size of Limb-Girdle Muscular Dystrophy (LGMD) in 2017
2.2. Global Market Size of Limb-Girdle Muscular Dystrophy (LGMD) in 2027
3. Disease Background and Overview: Limb-Girdle Muscular Dystrophy (LGMD)
3.1. Introduction
3.2. Causes
3.3. Types
3.4. Pathophysiology
3.5. Symptoms
3.6. Risk Factor
3.7. Diagnosis
4. Assumptions and Caveats
4.1. Limb-Girdle Muscular Dystrophy (LGMD) Geography Wise Prevalent Cases
4.1.1. 7MM Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.1.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.1.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.1.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.2. United States
4.2.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.2.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.2.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.2.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.3. EU-5
4.4. Germany
4.4.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.4.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.4.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.4.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.5. Italy
4.5.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.5.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.5.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.5.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.6. Spain
4.6.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.6.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.6.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.6.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.7. France
4.7.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.7.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.7.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.7.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.8. United Kingdom
4.8.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.8.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.8.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.8.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.9. Japan
4.9.1. Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.9.2. Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.9.3. Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
4.9.4. Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) (2016-2027)
5. Treatment Practices
5.1. Treatment Algorithm
5.2. Treatment Guidelines
6. Key Emerging Therapies
6.1. Key Cross Competition
6.2. MYO-101 : Myonexus Therapeutics
6.2.1. Regulatory Milestones
6.2.2. Clinical Development
6.2.3. Product Profile
6.2.4. Clinical Pipeline Activity
6.2.5. Ongoing Trials Information
6.2.6. Clinical Trial by Phase
6.3. ATYR1940 : aTyr Pharma
6.3.1. Regulatory Milestones
6.3.2. Clinical Development
6.3.3. Product Profile
6.3.4. Clinical Pipeline Activity
6.3.5. Ongoing Trials Information
6.3.6. Clinical Trial by Phase
To be continued in the report…
6.4. Current Unmet needs
7. Limb-Girdle Muscular Dystrophy (LGMD) Market Size
7.1. Key Findings
7.2. Total 7MM Limb-Girdle Muscular Dystrophy (LGMD) Market Analysis
7.3. Overview of Total Limb-Girdle Muscular Dystrophy (LGMD) Market
7.4. 7MM Limb-Girdle Muscular Dystrophy (LGMD): Country-Wise Market Analysis
7.4.1. United States
7.4.1.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.1.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.2. Germany
7.4.2.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.2.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.3. France
7.4.3.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.3.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.4. United Kingdom
7.4.4.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.4.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.5. Spain
7.4.5.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.5.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.6. Italy
7.4.6.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.6.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
7.4.7. Japan
7.4.7.1. Total Market Size of Limb-Girdle Muscular Dystrophy (LGMD)
7.4.7.2. Market Size of Limb-Girdle Muscular Dystrophy (LGMD) by Therapies
8. Market Drivers
9. Market Barriers
10. Report Methodology
10.1. Sources Used
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

Table 1 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Table 2 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Table 3 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Table 4 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Table 5 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Table 6 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Table 7 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Table 8 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Table 9 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Table 10 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Table 11 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Table 12 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Table 13 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Table 14 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Table 15 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Table 16 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Table 17 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Table 18 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Table 19 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Table 20 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Table 21 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Table 22 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Table 23 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Table 24 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Table 25 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Table 26 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Table 27 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Table 28 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Table 29 Treatment of manifestations
Table 30 Recommendations for practice
Table 31 Treatment for organ specific complications of Limb-Girdle Muscular Dystrophy (LGMD)
Table 32 MYO-101, Clinical Trials by Recruitment status, 2018
Table 33 MYO-101, Clinical Trials by Zone, 2018
Table 34 ATYR1940, Clinical Trials by Recruitment status, 2018
Table 35 ATYR1940, Clinical Trials by Zone, 2018
Table 36 Total 7 Major Market Size in USD, Million (2016-2027)
Table 37 Region wise Market Size in USD, Million (2016-2027)
Table 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 39 United States Market Size in USD, Million (2016-2027)
Table 40 United States Market Size by Therapy in USD, Million (2016-2027)
Table 41 Germany Market Size in USD, Million (2016-2027)
Table 42 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 43 France Market Size in USD, Million (2016-2027)
Table 44 France Market Size by Therapy in USD, Million (2016-2027)
Table 45 United Kingdom Market Size in USD, Million (2016-2027)
Table 46 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 47 Spain Market Size in USD, Million (2016-2027)
Table 48 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 49 Italy Market Size in USD, Million (2016-2027)
Table 50 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 51 Japan Market Size in USD, Million (2016-2027)
Table 52 Japan Market Size by Therapy in USD, Million (2016-2027)

Figure 1 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Figure 2 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Figure 3 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Figure 4 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the US (2016-2027)
Figure 5 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Figure 6 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Figure 7 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Figure 8 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Germany (2016-2027)
Figure 9 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Figure 10 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Figure 11 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Figure 12 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Italy (2016-2027)
Figure 13 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Figure 14 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Figure 15 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Figure 16 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Spain (2016-2027)
Figure 17 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Figure 18 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Figure 19 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Figure 20 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in France (2016-2027)
Figure 21 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Figure 22 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Figure 23 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Figure 24 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in the UK (2016-2027)
Figure 25 Prevalent Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Figure 26 Diagnosed Cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Figure 27 Type specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Figure 28 Severity specific cases of Limb-Girdle Muscular Dystrophy (LGMD) in Japan (2016-2027)
Figure 29 Treatment of manifestations
Figure 30 Recommendations for practice
Figure 31 Treatment for organ specific complications of Limb-Girdle Muscular Dystrophy (LGMD)
Figure 32 MYO-101, Clinical Trials by Recruitment status, 2018
Figure 33 MYO-101, Clinical Trials by Zone, 2018
Figure 34 ATYR1940, Clinical Trials by Recruitment status, 2018
Figure 35 ATYR1940, Clinical Trials by Zone, 2018
Figure 36 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 37 Region wise Market Size in USD, Million (2016-2027)
Figure 38 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 39 United States Market Size in USD, Million (2016-2027)
Figure 40 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 41 Germany Market Size in USD, Million (2016-2027)
Figure 42 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 43 France Market Size in USD, Million (2016-2027)
Figure 44 France Market Size by Therapy in USD, Million (2016-2027)
Figure 45 United Kingdom Market Size in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 47 Spain Market Size in USD, Million (2016-2027)
Figure 48 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 49 Italy Market Size in USD, Million (2016-2027)
Figure 50 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 51 Japan Market Size in USD, Million (2016-2027)
Figure 52 Japan Market Size by Therapy in USD, Million (2016-2027)